organization · Reporting owner
ORACLE INVESTMENT MANAGEMENT INC
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aspira Women's Health Inc.VRML · Entity 7871 | 10% owner · * See Remarks | August 31, 2017 | August 31, 2017 |
| BIOLASE, INCBIOL · Entity 11470 | 10% owner | December 04, 2017 | December 06, 2017 |
| SOLENO THERAPEUTICS INCSLNO · Entity 46432 | 10% owner | December 15, 2017 | December 26, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aspira Women's Health Inc.
Report date August 31, 2017 · Filed August 31, 2017
Jointly reported with FEINBERG LARRY N, ORACLE PARTNERS LP, Oracle Ten Fund Master, LP, ORACLE INSTITUTIONAL PARTNERS L P, Oracle Associates LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 9,825,289 |
Reported balance
After 2017-08-31 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-08-31 · Other · Acquired 583,333 · Balance 9,825,289 F1: See Exhibit 99.1, Note1. |
| Warrants to acquire Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2017-08-31 | IndirectSee footnote | 0 |
Reported balance
After 2017-08-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-08-31 · Other · Disposed 583,333 · Balance 0 F2: See Exhibit 99.1, Note 2. F1: See Exhibit 99.1, Note1. |
| Warrants to acquire Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2022-02-17 | IndirectSee footnote | 436,298 |
Reported balance
Holding disclosure · report date 2017-08-31 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 436,298 F3: See Exhibit 99.1, Note 3. |
Filing footnotes · ownership attribution and instrument terms
F1: See Exhibit 99.1, Note1.
F2: See Exhibit 99.1, Note 2.
F3: See Exhibit 99.1, Note 3.
BIOLASE, INC
Report date December 04, 2017 · Filed December 06, 2017
Jointly reported with FEINBERG LARRY N, ORACLE PARTNERS LP, Oracle Associates LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 30,866,265 |
Last balance in matching sequence
After 2017-12-05 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-12-04 · Purchase · Acquired 1,800,000 · Balance 20,120,650 F1: See Exhibit 99.1. Row 2 · 2017-12-05 · Purchase · Acquired 10,745,615 · Balance 30,866,265 F1: See Exhibit 99.1. |
Filing footnotes · ownership attribution and instrument terms
F1: See Exhibit 99.1.
SOLENO THERAPEUTICS INC
Report date December 15, 2017 · Filed December 26, 2017
Jointly reported with FEINBERG LARRY N, ORACLE PARTNERS LP, Oracle Associates LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 1,628,223 |
Reported balance
Holding disclosure · report date 2017-12-15 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,628,223 F1: These securities are owned by Oracle Partners, L.P. ("Partners"). F4: Larry N. Feinberg serves as the managing member of Oracle Associates, LLC, the general partner of Partners, Institutional Partners and Ten Fund, and accordingly, may be deemed to be the indirect beneficial owner of the shares beneficially owned by Partners, Institutional Partners and Ten Fund. Mr. Feinberg is the sole shareholder, director and president of Oracle Investment Management, Inc., which serves as investment manager to Partners, Institutional Partners and Ten Fund, and accordingly, may be deemed to be the beneficial owner of the shares beneficially owned by Partners, Institutional Partners and Ten Fund. Mr. Feinberg disclaims beneficial ownership of all such shares except to the extent of his pecuniary interest therein. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 217,096 |
Reported balance
Holding disclosure · report date 2017-12-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 217,096 F2: These securities are owned by Oracle Institutional Partners, L.P. ("Institutional Partners"). F4: Larry N. Feinberg serves as the managing member of Oracle Associates, LLC, the general partner of Partners, Institutional Partners and Ten Fund, and accordingly, may be deemed to be the indirect beneficial owner of the shares beneficially owned by Partners, Institutional Partners and Ten Fund. Mr. Feinberg is the sole shareholder, director and president of Oracle Investment Management, Inc., which serves as investment manager to Partners, Institutional Partners and Ten Fund, and accordingly, may be deemed to be the beneficial owner of the shares beneficially owned by Partners, Institutional Partners and Ten Fund. Mr. Feinberg disclaims beneficial ownership of all such shares except to the extent of his pecuniary interest therein. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 542,741 |
Reported balance
Holding disclosure · report date 2017-12-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 542,741 F3: These securities are owned by Oracle Ten Fund Master, L.P. ("Ten Fund"). F4: Larry N. Feinberg serves as the managing member of Oracle Associates, LLC, the general partner of Partners, Institutional Partners and Ten Fund, and accordingly, may be deemed to be the indirect beneficial owner of the shares beneficially owned by Partners, Institutional Partners and Ten Fund. Mr. Feinberg is the sole shareholder, director and president of Oracle Investment Management, Inc., which serves as investment manager to Partners, Institutional Partners and Ten Fund, and accordingly, may be deemed to be the beneficial owner of the shares beneficially owned by Partners, Institutional Partners and Ten Fund. Mr. Feinberg disclaims beneficial ownership of all such shares except to the extent of his pecuniary interest therein. |
| Warrants to acquire Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.00 | IndirectSee Footnotes | Not disclosed |
Reported balance
Holding disclosure · report date 2017-12-15 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F5: This figure represents warrants for 1,672,000 shares of Common Stock which are currently exercisable. The reporting person also owns warrants for 95,164 shares of Common Stock that are not currently exercisable due to restrictions on exercise that prevent the holder from exercising them to the extent it and its affiliates would beneficially own more than 19.99% of the Common Stock (the "19.99% Limitation"). F6: The warrants expire on the earlier to occur of (i) December 15, 2020 and (ii) 30 days following the announcement of positive Phase III results for Diazoxide Choline Controlled-Release tablet in Prader-Willi syndrome. F4: Larry N. Feinberg serves as the managing member of Oracle Associates, LLC, the general partner of Partners, Institutional Partners and Ten Fund, and accordingly, may be deemed to be the indirect beneficial owner of the shares beneficially owned by Partners, Institutional Partners and Ten Fund. Mr. Feinberg is the sole shareholder, director and president of Oracle Investment Management, Inc., which serves as investment manager to Partners, Institutional Partners and Ten Fund, and accordingly, may be deemed to be the beneficial owner of the shares beneficially owned by Partners, Institutional Partners and Ten Fund. Mr. Feinberg disclaims beneficial ownership of all such shares except to the extent of his pecuniary interest therein. F7: Partners owns warrants for 1,204,885 shares of Common Stock, Institutional Partners owns warrants for 160,651 shares of Common Stock and Ten Fund owns warrants for 401,628 shares of Common Stock. Warrants for 95,164 shares of Common Stock are not currently exercisable due to the 19.99% Limitation. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are owned by Oracle Partners, L.P. ("Partners").
F2: These securities are owned by Oracle Institutional Partners, L.P. ("Institutional Partners").
F3: These securities are owned by Oracle Ten Fund Master, L.P. ("Ten Fund").
F4: Larry N. Feinberg serves as the managing member of Oracle Associates, LLC, the general partner of Partners, Institutional Partners and Ten Fund, and accordingly, may be deemed to be the indirect beneficial owner of the shares beneficially owned by Partners, Institutional Partners and Ten Fund. Mr. Feinberg is the sole shareholder, director and president of Oracle Investment Management, Inc., which serves as investment manager to Partners, Institutional Partners and Ten Fund, and accordingly, may be deemed to be the beneficial owner of the shares beneficially owned by Partners, Institutional Partners and Ten Fund. Mr. Feinberg disclaims beneficial ownership of all such shares except to the extent of his pecuniary interest therein.
F5: This figure represents warrants for 1,672,000 shares of Common Stock which are currently exercisable. The reporting person also owns warrants for 95,164 shares of Common Stock that are not currently exercisable due to restrictions on exercise that prevent the holder from exercising them to the extent it and its affiliates would beneficially own more than 19.99% of the Common Stock (the "19.99% Limitation").
F6: The warrants expire on the earlier to occur of (i) December 15, 2020 and (ii) 30 days following the announcement of positive Phase III results for Diazoxide Choline Controlled-Release tablet in Prader-Willi syndrome.
F7: Partners owns warrants for 1,204,885 shares of Common Stock, Institutional Partners owns warrants for 160,651 shares of Common Stock and Ten Fund owns warrants for 401,628 shares of Common Stock. Warrants for 95,164 shares of Common Stock are not currently exercisable due to the 19.99% Limitation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 05, 2017 Filed Dec 6, 2017 16:33 UTC | BIOLASE, INC BIOL · Entity 11470 | PurchaseCommon Stock | 10,745,615 | $0.46 | $4,900,000.44 |
DisclosureSEC source: 0001140361-17-045190 · doc1.xml · nonDerivative · entry 2 FEINBERG LARRY N · CIK 0000926475 · 10% owner ORACLE PARTNERS LP · CIK 0000941901 · 10% owner Oracle Associates LLC · CIK 0001317217 · 10% owner ORACLE INVESTMENT MANAGEMENT INC · CIK 0001012622 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 30,866,265 F1 · ownership.nature: See Exhibit 99.1. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 16:33 UTC | BIOLASE, INC BIOL · Entity 11470 | PurchaseCommon Stock | 1,800,000 | $0.30 | $540,000.00 |
DisclosureSEC source: 0001140361-17-045190 · doc1.xml · nonDerivative · entry 1 FEINBERG LARRY N · CIK 0000926475 · 10% owner ORACLE PARTNERS LP · CIK 0000941901 · 10% owner Oracle Associates LLC · CIK 0001317217 · 10% owner ORACLE INVESTMENT MANAGEMENT INC · CIK 0001012622 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,120,650 F1 · ownership.nature: See Exhibit 99.1. Read SEC document |
| August 31, 2017 Filed Aug 31, 2017 19:43 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | OtherWarrants to acquire Common Stock · Derivative | 583,333 | Not disclosed Strike: $1.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-034022 · doc1.xml · derivative · entry 2 FEINBERG LARRY N · CIK 0000926475 · 10% owner · * See Remarks ORACLE PARTNERS LP · CIK 0000941901 · 10% owner · * See Remarks Oracle Ten Fund Master, LP · CIK 0001577258 · 10% owner · * See Remarks ORACLE INSTITUTIONAL PARTNERS L P · CIK 0000924141 · 10% owner · * See Remarks Oracle Associates LLC · CIK 0001317217 · 10% owner · * See Remarks ORACLE INVESTMENT MANAGEMENT INC · CIK 0001012622 · 10% owner · * See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 583,333 shares Expires 2017-08-31 F2 · price: See Exhibit 99.1, Note 2. F1 · ownership.nature: See Exhibit 99.1, Note1. Read SEC document |
| August 31, 2017 Filed Aug 31, 2017 19:43 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | OtherCommon Stock | 583,333 | $1.00 | $583,333.00 |
DisclosureSEC source: 0001140361-17-034022 · doc1.xml · nonDerivative · entry 1 FEINBERG LARRY N · CIK 0000926475 · 10% owner · * See Remarks ORACLE PARTNERS LP · CIK 0000941901 · 10% owner · * See Remarks Oracle Ten Fund Master, LP · CIK 0001577258 · 10% owner · * See Remarks ORACLE INSTITUTIONAL PARTNERS L P · CIK 0000924141 · 10% owner · * See Remarks Oracle Associates LLC · CIK 0001317217 · 10% owner · * See Remarks ORACLE INVESTMENT MANAGEMENT INC · CIK 0001012622 · 10% owner · * See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 9,825,289 F1 · ownership.nature: See Exhibit 99.1, Note1. Read SEC document |
| August 25, 2017 Filed Aug 30, 2017 20:57 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | PurchaseWarrants to acquire Common Stock · Derivative | 583,333 | Not disclosed Strike: $1.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-033837 · doc1.xml · derivative · entry 2 FEINBERG LARRY N · CIK 0000926475 · 10% owner · * See Remarks ORACLE PARTNERS LP · CIK 0000941901 · 10% owner · * See Remarks Oracle Ten Fund Master, LP · CIK 0001577258 · 10% owner · * See Remarks ORACLE INSTITUTIONAL PARTNERS L P · CIK 0000924141 · 10% owner · * See Remarks Oracle Associates LLC · CIK 0001317217 · 10% owner · * See Remarks ORACLE INVESTMENT MANAGEMENT INC · CIK 0001012622 · 10% owner · * See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 583,333 Underlying: Common Stock · 583,333 shares Expires 2017-08-31 F3 · derivative.exercise_price: See Exhibit 99.1, Note 3. F2 · kind: See Exhibit 99.1, Note 2. F2 · price: See Exhibit 99.1, Note 2. F3 · derivative.expiration_date: See Exhibit 99.1, Note 3. F1 · ownership.nature: See Exhibit 99.1, Note1. Read SEC document |
| August 25, 2017 Filed Aug 30, 2017 20:57 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | OtherWarrants to acquire Common Stock · Derivative | 583,333 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-033837 · doc1.xml · derivative · entry 1 FEINBERG LARRY N · CIK 0000926475 · 10% owner · * See Remarks ORACLE PARTNERS LP · CIK 0000941901 · 10% owner · * See Remarks Oracle Ten Fund Master, LP · CIK 0001577258 · 10% owner · * See Remarks ORACLE INSTITUTIONAL PARTNERS L P · CIK 0000924141 · 10% owner · * See Remarks Oracle Associates LLC · CIK 0001317217 · 10% owner · * See Remarks ORACLE INVESTMENT MANAGEMENT INC · CIK 0001012622 · 10% owner · * See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 583,333 shares Expires 2017-12-23 F2 · kind: See Exhibit 99.1, Note 2. F2 · price: See Exhibit 99.1, Note 2. F1 · ownership.nature: See Exhibit 99.1, Note1. Read SEC document |
| February 17, 2017 Filed Feb 17, 2017 17:10 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | PurchaseWarrant to acquire Common Stock · Derivative | 1 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-17-008151 · doc1.xml · derivative · entry 2 FEINBERG LARRY N · CIK 0000926475 · 10% owner · * See Remarks ORACLE PARTNERS LP · CIK 0000941901 · 10% owner Oracle Ten Fund Master, LP · CIK 0001577258 · 10% owner ORACLE INSTITUTIONAL PARTNERS L P · CIK 0000924141 · 10% owner Oracle Associates LLC · CIK 0001317217 · 10% owner ORACLE INVESTMENT MANAGEMENT INC · CIK 0001012622 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 583,333 shares Expires 2022-02-13 F2 · derivative.exercise_price: See Exhibit 99.1, Note 2. F3 · price: See Exhibit 99.1, Note 3. F1 · ownership.nature: See Exhibit 99.1, Note 1. Read SEC document |
| February 17, 2017 Filed Feb 17, 2017 17:10 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | PurchaseCommon Stock, par value $0.001 per share | 617,731 | $1.40 | $864,823.40 |
DisclosureSEC source: 0001140361-17-008151 · doc1.xml · nonDerivative · entry 1 FEINBERG LARRY N · CIK 0000926475 · 10% owner · * See Remarks ORACLE PARTNERS LP · CIK 0000941901 · 10% owner Oracle Ten Fund Master, LP · CIK 0001577258 · 10% owner ORACLE INSTITUTIONAL PARTNERS L P · CIK 0000924141 · 10% owner Oracle Associates LLC · CIK 0001317217 · 10% owner ORACLE INVESTMENT MANAGEMENT INC · CIK 0001012622 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 9,825,289 F1 · price: See Exhibit 99.1, Note 1. F1 · ownership.nature: See Exhibit 99.1, Note 1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.